These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29762239)

  • 1. Quality and Safety in Health Care, Part XLIV: Cardiac Resynchronization Therapy and Subcutaneous Defibrillator Implantable Devices.
    Harolds JA
    Clin Nucl Med; 2019 Feb; 44(2):119-120. PubMed ID: 29762239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased late complex device infections are determined by cardiac resynchronization therapy-defibrillator infection.
    Unsworth JD; Zaidi A; Hargreaves MR
    Europace; 2015 Nov; 17(11):1708-11. PubMed ID: 25883081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection and outcome of implantable cardioverter-defibrillator patients with and without cardiac resynchronization therapy: Comparison of 4384 patients from the German Device Registry to randomized controlled trials.
    Köbe J; Willy K; Senges J; Hochadel M; Kleemann T; Spitzer SG; Andresen D; Jehle J; Steinbeck G; Szendey I; Butter C; Brachmann J; Hoffmann E; Eckardt L
    J Cardiovasc Electrophysiol; 2022 Mar; 33(3):483-492. PubMed ID: 35028995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defibrillators: Selecting the Right Device for the Right Patient.
    Al-Khatib SM; Friedman P; Ellenbogen KA
    Circulation; 2016 Nov; 134(18):1390-1404. PubMed ID: 27799257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One Indication for an Extravascular Cardiac Resynchronization Therapy Defibrillator: Lessons from a Combination Therapy Case with Epicardial Cardiac Resynchronization Therapy and a Subcutaneous Implantable Cardioverter Defibrillator.
    Ishii N; Nakajima K; Kakuta T; Noda T; Fujita T; Kusano K
    Intern Med; 2021 Jun; 60(12):1877-1880. PubMed ID: 33518564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.
    Khazanie P; Greiner MA; Al-Khatib SM; Piccini JP; Turakhia MP; Varosy PD; Masoudi FA; Curtis LH; Hernandez AF;
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block.
    Biton Y; Zareba W; Goldenberg I; Klein H; McNitt S; Polonsky B; Moss AJ; Kutyifa V;
    J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26124205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of intermittent atrial tachyarrhythmia on heart failure or death in cardiac resynchronization therapy with defibrillator versus implantable cardioverter-defibrillator patients: a MADIT-CRT substudy (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).
    Ruwald AC; Pietrasik G; Goldenberg I; Kutyifa V; Daubert JP; Ruwald MH; Jons C; McNitt S; Wang P; Zareba W; Moss AJ
    J Am Coll Cardiol; 2014 Apr; 63(12):1190-1197. PubMed ID: 24333490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complications in recipients of cardioverter-defibrillator or cardiac resynchronization therapy: Insights from Silesian Center Defibrillator registry.
    Tajstra M; Gadula-Gacek E; Kurek A; Adamowicz-Czoch E; Olszowski D; Ostręga M; Ciślak A; Pyka Ł; Hawranek M; Lekston A; Poloński L; Gąsior M
    Cardiol J; 2017; 24(5):515-522. PubMed ID: 27734455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The subcutaneous ICD as an alternative to the conventional ICD system: Initial experience in Greece and a review of the literature.
    Sideris S; Archontakis S; Gatzoulis KA; Anastasakis A; Sotiropoulos I; Arsenos P; Kasiakogias A; Terentes D; Trachanas K; Paschalidis E; Tousoulis D; Kallikazaros I
    Hellenic J Cardiol; 2017; 58(1):4-16. PubMed ID: 28163146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replacement of implantable cardioverter defibrillators and cardiac resynchronization therapy devices: results of the European Heart Rhythm Association survey.
    Tilz R; Boveda S; Deharo JC; Dobreanu D; Haugaa KH; Dagres N
    Europace; 2016 Jun; 18(6):945-9. PubMed ID: 27297231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study.
    Masoudi FA; Mi X; Curtis LH; Peterson PN; Curtis JP; Fonarow GC; Hammill SC; Heidenreich PA; Al-Khatib SM; Piccini JP; Qualls LG; Hernandez AF
    Ann Intern Med; 2014 May; 160(9):603-11. PubMed ID: 24798523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Battery drain in daily practice and medium-term projections on longevity of cardioverter-defibrillators: an analysis from a remote monitoring database.
    Boriani G; Ritter P; Biffi M; Ziacchi M; Diemberger I; Martignani C; Valzania C; Valsecchi S; Padeletti L; Gadler F
    Europace; 2016 Sep; 18(9):1366-73. PubMed ID: 26847076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy.
    Kutyifa V; Stockburger M; Daubert JP; Holmqvist F; Olshansky B; Schuger C; Klein H; Goldenberg I; Brenyo A; McNitt S; Merkely B; Zareba W; Moss AJ
    Circ Arrhythm Electrophysiol; 2014 Aug; 7(4):645-51. PubMed ID: 24963007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candidacy for a Subcutaneous Implantable Cardioverter Defibrillator in Patients with Cardiac Resynchronization Therapy.
    Kawabata M; Goya M; Takahashi Y; Maeda S; Yagishita A; Shirai Y; Kaneko M; Shiohira S; Hirao K
    Int Heart J; 2018 Sep; 59(5):951-958. PubMed ID: 30101850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical course of patients with implantable cardioverter-defibrillators: Extended experience on clinical outcome, device replacements, and device-related complications.
    van der Heijden AC; Borleffs CJ; Buiten MS; Thijssen J; van Rees JB; Cannegieter SC; Schalij MJ; van Erven L
    Heart Rhythm; 2015 Jun; 12(6):1169-76. PubMed ID: 25749138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
    Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
    J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
    Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
    Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eligibility of cardiac resynchronization therapy patients for subcutaneous implantable cardioverter defibrillators.
    Moubarak G; Maison-Blanche P; Thomas O
    J Electrocardiol; 2018; 51(3):531-533. PubMed ID: 29273233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complications of permanent cardiac pacing in patients with persistent left superior vena cava.
    Polewczyk A; Kutarski A; Czekajska-Chehab E; Adamczyk P; Boczar K; Polewczyk M; Janion M
    Cardiol J; 2014; 21(2):128-37. PubMed ID: 24526508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.